FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313579804> ?p ?o ?g. }

• W4313579804 endingPage "477" @default.
• W4313579804 startingPage "473" @default.
• W4313579804 abstract "Introduction. The change in the classical etiological paradigm of hepatocellular carcinoma has led to the fact that non-alcoholic fatty liver disease is now the fastest growing cause of hepatocellular carcinoma in the world. Purpose. To study the range of medicines and analyze the costs of drug provision for a determined population of patients with non-alcoholic fatty liver disease in Moscow over a three-year period. Materials and methods. Based on data from the Moscow Department of Health on preferential drug coverage for the period from 2019 to 2021 the range of drug therapy and the economic costs. Results. For 3 years, seventeen thousand two hundred ten patients with a diagnosis of non-alcoholic fatty liver disease received preferential drug coverage in Moscow, and the amount of costs minus payment by the patient amounted to 49,102,963.97 rubles. The most prescribed drugs were drugs from the group of “hepatoprotectors”. An increase in the population of patients with non-alcoholic fatty liver disease over a three-year period by 1.7 times, an increase in the cost of its drug provision. Along with this, the prevalence in the spectrum of drugs was revealed: glycyrrhizic acid + phospholipids; phospholipids; ursodeoxycholic acid; ademetionine is not found in international practice and is not funded under the nosology “non-alcoholic fatty liver disease”. Limitations. When studying options for drug provision of patients with non -alcoholic fatty liver disease, we had an assessment of 17,210 observations, which is a sufficient reference sample Conclusion. Analysis of the qualitative and quantitative composition of the population of patients with non-alcoholic fatty liver disease can be an effective tool for predicting the social and economic burden of the disease and can be used for rational planning of budget expenditures of all levels." @default.
• W4313579804 created "2023-01-06" @default.
• W4313579804 creator A5002490938 @default.
• W4313579804 creator A5003327852 @default.
• W4313579804 date "2022-12-12" @default.
• W4313579804 modified "2023-09-30" @default.
• W4313579804 title "Characteristics and analysis of the costs of drug provision of patients with non-alcoholic fatty liver disease in Moscow" @default.
• W4313579804 cites W2204688218 @default.
• W4313579804 cites W2268419391 @default.
• W4313579804 cites W2744982526 @default.
• W4313579804 cites W2944885259 @default.
• W4313579804 cites W3117083078 @default.
• W4313579804 cites W3124793833 @default.
• W4313579804 cites W3158102012 @default.
• W4313579804 cites W3187429094 @default.
• W4313579804 cites W3193498370 @default.
• W4313579804 cites W3203386040 @default.
• W4313579804 cites W3208129759 @default.
• W4313579804 cites W3211488171 @default.
• W4313579804 cites W4281711803 @default.
• W4313579804 doi "https://doi.org/10.47470/0044-197x-2022-66-6-473-477" @default.
• W4313579804 hasPublicationYear "2022" @default.
• W4313579804 type Work @default.
• W4313579804 citedByCount "0" @default.
• W4313579804 crossrefType "journal-article" @default.
• W4313579804 hasAuthorship W4313579804A5002490938 @default.
• W4313579804 hasAuthorship W4313579804A5003327852 @default.
• W4313579804 hasBestOaLocation W43135798041 @default.
• W4313579804 hasConcept C126322002 @default.
• W4313579804 hasConcept C2777075537 @default.
• W4313579804 hasConcept C2777214474 @default.
• W4313579804 hasConcept C2777575235 @default.
• W4313579804 hasConcept C2778772119 @default.
• W4313579804 hasConcept C2779134260 @default.
• W4313579804 hasConcept C2780035454 @default.
• W4313579804 hasConcept C2908647359 @default.
• W4313579804 hasConcept C71924100 @default.
• W4313579804 hasConcept C90924648 @default.
• W4313579804 hasConcept C98274493 @default.
• W4313579804 hasConcept C99454951 @default.
• W4313579804 hasConceptScore W4313579804C126322002 @default.
• W4313579804 hasConceptScore W4313579804C2777075537 @default.
• W4313579804 hasConceptScore W4313579804C2777214474 @default.
• W4313579804 hasConceptScore W4313579804C2777575235 @default.
• W4313579804 hasConceptScore W4313579804C2778772119 @default.
• W4313579804 hasConceptScore W4313579804C2779134260 @default.
• W4313579804 hasConceptScore W4313579804C2780035454 @default.
• W4313579804 hasConceptScore W4313579804C2908647359 @default.
• W4313579804 hasConceptScore W4313579804C71924100 @default.
• W4313579804 hasConceptScore W4313579804C90924648 @default.
• W4313579804 hasConceptScore W4313579804C98274493 @default.
• W4313579804 hasConceptScore W4313579804C99454951 @default.
• W4313579804 hasIssue "6" @default.
• W4313579804 hasLocation W43135798041 @default.
• W4313579804 hasOpenAccess W4313579804 @default.
• W4313579804 hasPrimaryLocation W43135798041 @default.
• W4313579804 hasRelatedWork W2012739792 @default.
• W4313579804 hasRelatedWork W2054776754 @default.
• W4313579804 hasRelatedWork W2317783377 @default.
• W4313579804 hasRelatedWork W2464375531 @default.
• W4313579804 hasRelatedWork W2494166375 @default.
• W4313579804 hasRelatedWork W2986439861 @default.
• W4313579804 hasRelatedWork W3013910762 @default.
• W4313579804 hasRelatedWork W3023642560 @default.
• W4313579804 hasRelatedWork W3032685137 @default.
• W4313579804 hasRelatedWork W4226323221 @default.
• W4313579804 hasVolume "66" @default.
• W4313579804 isParatext "false" @default.
• W4313579804 isRetracted "false" @default.
• W4313579804 workType "article" @default.